Zimbabwe has rejected a significant American healthcare agreement worth 367 million US dollars (272 million pounds) over five years due to Washington's insistence on confidential biological samples.
This rejection was revealed after a internal memorandum dated December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the deal was "lopsided".
A government spokesperson has since explained that the US was demanding access to health data for research and profit but was unwilling to guarantee the resulting advantages from future treatments.
"We are forced to start the difficult and regrettable task of ending our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had provided over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged continued negotiations to reach a agreement acceptable to all parties so the country's critical HIV programme can be sustained.
Broader Background
This development comes after a comparable case in Kenya, where a high court suspended a similar health funding agreement following legal challenges were raised about the security of citizens' health data.
Since returning to the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
The agency had administered aid for the American government, but Trump argued its expenditure was "inefficient" and his administration was seeking direct bilateral deals to enhance transparency and responsibility.
As per reports, Sixteen African countries have so far signed these new agreements, representing over $18.3bn in new funding.
Specifics of the Declined Deal
The money for Zimbabwe would have supported "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this partnership would have delivered immense advantages for the people of Zimbabwe, especially the 1.2 million presently receiving antiretroviral therapy through American-funded initiatives," Tremont commented.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"Our nation was requested to surrender its biological resources and data for a long time, without any equivalent guarantee of access to any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," he stated.
"Effectively, our country would supply the basic resources for scientific discovery without any certainty that the final treatments would be available to our population if a future health crisis arise."
Sovereignty and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its push of bilateral deals were upending systems already set up via the global health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing system created to deal with future global health emergencies.
"This system is designed to guarantee that when a nation contributes its data, the benefits – including medicines and cures – are shared equitably, not commercialised exclusively by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We encourage ongoing dialogue with our US partners on how future co-operation might be structured in a way that honours the independence and dignity of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the government's concerns, but suggested that negotiations need to persist considering a large portion of the nation's Aids initiatives depended on international support.
"If technical issues exist, including those relating to information security or agreement terms, these can often be resolved via detailed discussion and mutually agreed protections," it said.
The situation underscores the ongoing debate between accepting crucial international aid and safeguarding local interests in an ever more data-driven world.